

Title (en)  
PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM

Title (de)  
PHARMAZEUTISCHE ZUSAMMENSETZUNGEN MIT MELOXICAM

Title (fr)  
COMPOSITIONS PHARMACEUTIQUES COMPRENANT DU MÉLOXICAM

Publication  
**EP 4132511 A4 20240515 (EN)**

Application  
**EP 21784898 A 20210406**

Priority

- US 202063006023 P 20200406
- US 202016841436 A 20200406
- US 202016842063 A 20200407
- US 202016867929 A 20200506
- US 2021026027 W 20210406

Abstract (en)  
[origin: WO2021207253A1] Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

IPC 8 full level  
**A61K 9/20** (2006.01); **A61K 31/4196** (2006.01); **A61K 31/5415** (2006.01); **A61K 31/724** (2006.01); **A61K 33/10** (2006.01); **A61K 47/69** (2017.01); **A61P 29/00** (2006.01); **A61K 9/24** (2006.01)

CPC (source: AU EP KR)  
**A61K 9/0053** (2013.01 - AU); **A61K 9/2009** (2013.01 - EP); **A61K 9/205** (2013.01 - EP); **A61K 31/4196** (2013.01 - AU EP KR); **A61K 31/5415** (2013.01 - AU EP KR); **A61K 31/724** (2013.01 - EP); **A61K 33/10** (2013.01 - EP); **A61K 47/02** (2013.01 - AU KR); **A61K 47/61** (2017.07 - AU); **A61K 47/6951** (2017.07 - AU EP KR); **A61P 25/06** (2017.12 - AU KR); **A61P 29/00** (2017.12 - EP); **A61K 9/0053** (2013.01 - KR); **A61K 9/209** (2013.01 - EP); **A61K 2300/00** (2013.01 - AU KR); **A61P 1/08** (2017.12 - AU); **A61P 27/00** (2017.12 - AU); **B82Y 5/00** (2013.01 - EP)

C-Set (source: AU EP)  
AU  
1. **A61K 31/5415 + A61K 2300/00**  
2. **A61K 31/4196 + A61K 2300/00**  
EP  
1. **A61K 31/724 + A61K 2300/00**  
2. **A61K 31/5415 + A61K 2300/00**  
3. **A61K 31/4196 + A61K 2300/00**  
4. **A61K 33/10 + A61K 2300/00**

Citation (search report)

- [X1] US 2020085954 A1 20200319 - TABUTEAU HERRIOT [US]
- See references of WO 2021207253A1

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)  
**WO 2021207253 A1 20211014**; CA 3179681 A1 20211014; CN 115697326 A 20230203; EP 4132511 A1 20230215; EP 4132511 A4 20240515; JP 2023520574 A 20230517; KR 20220164557 A 20221213

DOCDB simple family (application)  
**US 2021026027 W 20210406**; CA 3179681 A 20210406; CN 202180039884 A 20210406; EP 21784898 A 20210406; JP 2022560874 A 20210406; KR 20227038594 A 20210406